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Summary: EVAR requires preoperative device selection, proper interpretation of complex imaging, and a high-level of technical competence to allow precise and facile placement without complication. The skills needed for EVAR are readily adaptable to virtual reality simulation training and it was thought that training would improve overall skills resulting in a decreased procedural time, fewer complications and better selection of appropriately sized devices. The simulator was a Simbionix Angiomentor (3D Systems Healthcare, Golden, Colo). It has 10 different inbuilt EVAR modules and automatically records several technical parameters (time, amount of contrast used, contact of wires/catheters with the wall, presence and details of endoleaks, choice of device[s]) as well as patient-related metrics (heart rate, blood pressure, electrocardiogram, medications given). Six staff consultants familiar with the simulator preformed an uncomplicated EVAR and data was recorded as benchmark metrics. Sixteen vascular trainees were asked to preform the same EVAR procedure as the staff consultants after a brief familiarization with the simulator and data collected. The trainees were given 1:1 supervision and feedback during 4 training sessions (supervised simulation based training) and were then asked to do the same EVAR as the baseline deployment on training completion. In addition to the automatic simulator data collection points, a Likertscore of trainee performance was also completed by two independent assessors during conduct of the unaided EVAR deployment at both baseline and final run. At baseline, the consultants performed the procedure in 45 minutes, always chose appropriate devices and experienced no endoleaks on completion angiogram. After training, the participants demonstrated improved EVAR procedure times 77 to 56 minutes (P < .0001). The mean Likert-scale scores improved significantly (P < .0001) from 16.6 (standard deviation, 1.46) to 28.63 (standard deviation, 2.986). There were less type 1 endoleak (P ¼ .0063) and an intra-arterial catheter was advanced fewer times without a wire (P ¼ .002). Finally, trainees were more likely to choose a device of appropriate size (50% vs 12.5% after training, P ¼ .0063).
Comments: Much like any technically demanding job, detailed instruction including simulation is becoming standard fare (ie, pilot training/retraining, fundamentals of laparoscopic surgery). Add the ever increasing technical demands associated with our field to training time constraints, and you have a ripe field for simulation training. This study adds one more to the increasing numbers demonstrating that technical performance can be improved with simulation training. To become a mandatory component of our training paradigms, confirmation that skills learned here are transferable to the clinic is paramount. A practical need for most program directors is appropriate training (which might include simulators) at a reasonable cost.
Ticagrelor Versus Clopidogrel in Symptomatic Peripheral Artery Disease
Hiatt WR, Fowkes FG, Heizer G, Berger JS, Baumgartner I, Held P, et al. N Engl J Med 2017; 376:32-40. Conclusions: In patients with symptomatic peripheral artery disease (PAD), ticagrelor was not superior to clopidogrel for the reduction of cardiovascular events. Each drug was associated with similar rates of major bleeding. However, ticagrelor was discontinued more frequently than clopidogrel because of the occurrence of side effects mainly dyspnea and minor bleeding.
Summary: This double-blinded randomized trial of patients with symptomatic PAD received either 90 mg twice per day of ticagrelor or 75 mg once day of clopidogrel. Patients were included if they were $ 50 years of age, their ankle/brachial index (ABI) was # 0.8 or if they had previous lower limb revascularization. If the patient had an ABI of $ 1.4 indicative of calcified tibial arteries, a toe/brachial index (TBI) of # 0.6 qualified the patient for inclusion into the study. Key exclusion criteria were current or planned use of dual antiplatelet therapy or aspirin, an increased risk of bleeding, treatment with long-term anticoagulation, or a poor clopidogrel metabolizer status for the cytochrome P-450 2C19 allele, defined as a genotype with two loss-of-function alleles. The primary efficacy endpoint was the first occurrence of any event in the composite score of cardiovascular death, myocardial infarction or stroke (not shown to be primarily hemorrhagic). Key secondary end points included any of the above three events occurring after a first occurrence or acute limb ischemia requiring hospitalization and was considered a combined outcome for analyses. The primary safety end point was major bleeding. The median follow-up was 30 months. The randomization process was double-blinded in a 1:1 ratio. The analyses were performed according to intention-to-treat and included all the patients who had undergone randomization. AstraZeneca provided financial support for the conduct of the study and aided in the study design but the clinical database was housed at Duke Clinical Research Institute and Institute staff, independent of the sponsor, conducted all analyses. There were 13, 885 patients who were recruited for the study from 811 sites in 28 countries. Patient characteristics were well matched between the two treatment groups. The median age was 66 years old and 72% were male. The basis for enrollment was an abnormal ABI in 43% and prior revascularization in 57%. Five percent of asymptomatic patients had not undergone a previous revascularization, which means that these patients were recruited only based on an abnormal ABI. The mean ABI at baseline was 0.71 and claudication was present in 76.6% of patients while 4.6% reported critical limb ischemia. Nearly identical primary efficacy and safety end points are reported for both drugs. A primary efficacy end point was observed in 751 of 6930 patients receiving ticagrelor (10.8%) and in 740 of 6955 patients receiving clopidogrel (10.6%; P ¼ .65). The only significant difference between groups was the rate of ischemic stroke, which occurred in 1.9% of the patients in the ticagrelor group vs 2.4% in the clopidogrel group (P ¼ .03) but these numbers were so small that they did not influence the overall analytics. The key secondary efficacy outcome occurred in 12.1% in the ticagrelor group and 12.0% in the clogidogrel group (P ¼ .74). Acute limb ischemia occurred in 1.7% of patients in each group (P ¼ .85). There was one group of patients in which ticagrelor was more efficacious and that was noted in the group of patients who had undergone prior coronary or carotid revascularization or previous coronary artery stenting (data provided in the Supplementary Appendix). There was a 1.6% rate of major bleeding in both groups (P ¼ .49). There were numerically fewer fatal bleeding events in the ticagrelor group than in the clopidogrel group (10 vs 20; P ¼ .10), but there were significantly more bleeding events leading to discontinuation with ticagrelor than with clopidogrel (168 vs 112; P < .001). Ticagrelor was prematurely discontinued more often than clopidogrel during the study (30.1% vs 25.9%; P < .001) driven mainly by the occurrence of dyspnea (4.8% vs 0.8%; P < .001) and any bleeding event (2.4% vs 1.6%; P < .001).
Comments: The CAPRIE (Clopidogrel vs Aspirin (ASA) in Patients at Risk of Ischemic Events; CAPRIE Steering Committee. A randomized, blinded, trial of clopidogrel vs aspirin in patients at risk of ischaemic events (CAPRIE). Lancet 1996;348:1329-39) demonstrated a significant benefit of clopidogrel over ASA in cardiovascular risk reduction driven mainly by the subgroup of patients with PAD (23.8%). Dual therapy (ASA/clopidogrel) is not the answer since it has been associated with added bleeding risk without improved efficacy. Ticagrelor, when studied in patients with cardiac disease, was more efficacious in reducing the rate of cardiovascular events than ASA with potentially more benefit in those with PAD. A direct comparison of clopidogrel to ticagrelor seemed a logical next step in the quest for best medical therapy to prevent cardiovascular events in patients with PAD. In my mind, the study was well-designed, conducted and analyzed with sufficient numbers to make a statistically valid conclusion. Either can be used in our vascular patients to prevent cardiovascular death, myocardial infarction, or stroke and with similar risks of major bleeding. However, the increased rate of side effects with ticagrelor use, resulting in early discontinuation of the drug, makes it less appealing as the go-to treatment.
